Novel Therapeutics for Liver Fibrosis

Bast Biotechnology has developed innovative technology to fight fibrotic disease.  The intial indication will target non-alcolic fibrotic liver disease (NAFLD) and non-alcoholic steatosis hepatitis (NASH).

Print Print | Sitemap
© Bast Biotechnology - Powered by 1&1 IONOS